<code id='2407D02C51'></code><style id='2407D02C51'></style>
    • <acronym id='2407D02C51'></acronym>
      <center id='2407D02C51'><center id='2407D02C51'><tfoot id='2407D02C51'></tfoot></center><abbr id='2407D02C51'><dir id='2407D02C51'><tfoot id='2407D02C51'></tfoot><noframes id='2407D02C51'>

    • <optgroup id='2407D02C51'><strike id='2407D02C51'><sup id='2407D02C51'></sup></strike><code id='2407D02C51'></code></optgroup>
        1. <b id='2407D02C51'><label id='2407D02C51'><select id='2407D02C51'><dt id='2407D02C51'><span id='2407D02C51'></span></dt></select></label></b><u id='2407D02C51'></u>
          <i id='2407D02C51'><strike id='2407D02C51'><tt id='2407D02C51'><pre id='2407D02C51'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          comprehensive

          author:explore    - browse:4

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia